Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery
Surgery may leads to higher serious adverse events (number of participants) compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery
Surgery may leads to higher serious adverse events (number of events) compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes mortality at maximal compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Cancer‐related mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
Percutaneous alcohol injection may leads to higher cancer‐related mortality at maximal compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of events) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · adults with chronic hepatitis C
It is very uncertain whether direct‐acting antivirals changes all‐cause mortality at maximum compared with control (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse event at maximum · adults with chronic hepatitis C
It is very uncertain whether direct‐acting antivirals changes proportion of participants with one or more serious adverse event at… compared with control (very low certainty).
1 finding from 1 review
Proportion of participants with no sustained virological response at maximum · adults with chronic hepatitis C
Direct‐acting antivirals may leads to lower proportion of participants with no sustained virological response at… compared with control (low certainty).
1 finding from 1 review
All‐cause mortality maximum · adults with chronic hepatitis C
It is very uncertain whether direct‐acting antivirals withdrawn from the market changes all‐cause mortality at maximum compared with control (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse event at maximum · adults with chronic hepatitis C
It is very uncertain whether direct‐acting antivirals withdrawn from the market changes proportion of participants with one or more serious adverse event at… compared with control (very low certainty).
1 finding from 1 review
Proportion of participants with no sustained virological response at maximum · adults with chronic hepatitis C
Direct‐acting antivirals withdrawn from the market may leads to lower proportion of participants with no sustained virological response at… compared with control (low certainty).
1 finding from 1 review
All‐cause mortality · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower mortality compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).
1 finding from 1 review
Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower hepatic encephalopathy compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower serious adverse events compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Secondary outcome: quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low